We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.
TODAY'S HIGH
114.5
TODAY'S LOW
107.7
52 WEEK HIGH
227.9
52 WEEK LOW
97.7
% of Shares Held by
All Insider
77.55%
% of Shares Held by
Institutions
0.00%
% of Float Held by
Institutions
0.00%
Number of Institutions
Holding Shares
0
MARKET CAP
242.44 Cr.
ETERPRISE VALUE
382.06 Cr.
NO. OF SHARES
2.15 Cr.
BOOK VALUE
-35.775
DIV. YIELD
2.892983%
DEBT
142.91 Cr.
GROSS PROFIT
13.99 Cr.
CASH
10.06 Lakhs
REVENUE
63.58 Cr.
REVENUE/SHARE
29.463
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 0 | 0 | 0 | 0 |
| Change To Liabilities | 17.12 Cr. | -1.87 Cr. | 1.25 Cr. | 3.78 Cr. |
| Total cashflows from Investing Activities | -22.89 Cr. | -22.54 Cr. | -10.22 Cr. | -4.31 Cr. |
| Net Borrowings | 32.38 Cr. | 33.49 Cr. | 15.06 Cr. | -1.26 Cr. |
| Total Cash from Financing Activities | 39.50 Cr. | 37.66 Cr. | 28.57 Cr. | 17.32 Cr. |
| Other Liabilities | 8.30 Cr. | 5.68 Cr. | -13.50 Cr. | 9.74 Cr. |
| Total Assets | 12.51 Cr. | 10.44 Cr. | 19.43 Cr. | 24.82 Cr. |
| Net Income | -44.52 Cr. | -28.35 Cr. | -28.87 Cr. | -20.01 Cr. |
| Change in Cash | -61.01 Lakhs | 53.64 Lakhs | -17.14 Cr. | 16.90 Cr. |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | -17.21 Cr. | -14.57 Cr. | -35.49 Cr. | 3.89 Cr. |
| Depreciation | 6.29 Cr. | 4.86 Cr. | 4.41 Cr. | 4.18 Cr. |
| Other Cashflows from Investing Activities | 4.17 Cr. | 2.95 Cr. | -81.11 Lakhs | 88.55 Lakhs |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Change to Inventory | -8.96 Cr. | -1.60 Cr. | -6.03 Cr. | 2.76 Cr. |
| Change to Account Receivables | -57.67 Lakhs | -9.77 Lakhs | 2.70 Cr. | -2.58 Cr. |
| Other Cashflows from Financing Activities | -5.39 Cr. | -6.27 Cr. | -5.92 Cr. | -6.23 Cr. |
| Change to Net Income | 5.11 Cr. | 6.55 Cr. | 4.27 Cr. | 5.79 Cr. |
| Capital Expenditures | -27.07 Cr. | -25.50 Cr. | -9.41 Cr. | -4.33 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | -44.52 Cr. | -28.35 Cr. | -28.87 Cr. | -20.01 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | -39.13 Cr. | -22.15 Cr. | -23.13 Cr. | -13.90 Cr. |
| Selling General Administrative | 15.30 Cr. | 16.77 Cr. | 15.97 Cr. | 15.80 Cr. |
| Gross Profit | -13.99 Cr. | 1.08 Cr. | 9.49 Lakhs | 8.33 Cr. |
| Ebit | -39.13 Cr. | -22.15 Cr. | -23.13 Cr. | -13.90 Cr. |
| Operating Income | -39.13 Cr. | -22.15 Cr. | -23.13 Cr. | -13.90 Cr. |
| Other Operating Expenses | 3.54 Cr. | 1.25 Cr. | 2.57 Cr. | 2.01 Cr. |
| Interest Expense | -5.39 Cr. | -6.27 Cr. | -5.99 Cr. | -6.27 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Total Revenue | 59.70 Cr. | 52.68 Cr. | 32.39 Cr. | 46.74 Cr. |
| Total Operating Expenses | 98.83 Cr. | 74.83 Cr. | 55.53 Cr. | 60.64 Cr. |
| Cost of Revenue | 73.70 Cr. | 51.59 Cr. | 32.30 Cr. | 38.41 Cr. |
| Total Other Income Expense Net | -5.39 Cr. | -6.20 Cr. | -5.73 Cr. | -6.10 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | -44.52 Cr. | -28.35 Cr. | -28.87 Cr. | -20.01 Cr. |
| Net Income Applicable to Common Shares | -44.52 Cr. | -28.35 Cr. | -28.87 Cr. | -20.01 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 1.84 Cr. | 1.84 Cr. | 1.84 Cr. | 1.84 Cr. |
| Capital Surplus | 0 | 103.27 Cr. | 90.96 Cr. | 80.54 Cr. |
| Total Liabilities | 264.89 Cr. | 201.95 Cr. | 158.79 Cr. | 156.65 Cr. |
| Stock Holder Equity | -75.09 Cr. | -42.73 Cr. | -24.99 Cr. | -14.28 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 29 Cr. | 7.04 Cr. | 8.68 Cr. | 8.30 Cr. |
| Total Assets | 189.80 Cr. | 159.22 Cr. | 133.80 Cr. | 142.36 Cr. |
| Common Stock | 21.56 Cr. | 19.62 Cr. | 18 Cr. | 16.63 Cr. |
| Retained Earnings | 0 | -181.24 Cr. | -153.05 Cr. | -122.92 Cr. |
| Other Liabilities | 53.90 Cr. | 53.21 Cr. | 50.15 Cr. | 51.56 Cr. |
| Good Will | 0 | 0 | 0 | 0 |
| Treasury Stock | -96.65 Cr. | 15.61 Cr. | 19.09 Cr. | 11.45 Cr. |
| Other Assets | 8.24 Cr. | 9.60 Cr. | 7.38 Cr. | 8.82 Cr. |
| Cash | 10.06 Lakhs | 71.07 Lakhs | 17.43 Lakhs | 17.31 Cr. |
| Current Liabilities | 78.06 Cr. | 48.19 Cr. | 43.13 Cr. | 54.86 Cr. |
| Long Term Asset Charges | 0 | 0 | 0 | 0 |
| Short Long Term Debt | 0 | 59.18 Lakhs | 70.68 Lakhs | 3.15 Cr. |
| Other Stockholder Equity | -96.65 Cr. | 15.61 Cr. | 19.09 Cr. | 11.45 Cr. |
| Property Plant Equipment | 144.21 Cr. | 126.35 Cr. | 105.71 Cr. | 100.71 Cr. |
| Total Cur. Assets | 35.49 Cr. | 21.41 Cr. | 18.85 Cr. | 30.97 Cr. |
| Long Term Investments | 0 | 0 | 0 | 0 |
| Net Tangible Assets | -76.94 Cr. | -44.58 Cr. | -26.84 Cr. | -16.13 Cr. |
| Short Term Investments | 0 | 0 | 0 | 0 |
| Net Receivables | 87.65 Lakhs | 37.64 Lakhs | 27.38 Lakhs | 2.98 Cr. |
| Long Term Debt | 132.93 Cr. | 100.54 Cr. | 65.50 Cr. | 50.22 Cr. |
| Inventory | 25.56 Cr. | 16.89 Cr. | 15.38 Cr. | 9.24 Cr. |
| Accounts Payable | 37.90 Cr. | 17.24 Cr. | 20.03 Cr. | 18.64 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account